LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Zurück zur letzten Suche Suchhistorie
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Millburn, Michael V"
  2. AU="Ciebiera, Małgorzata"
  3. AU="Granich, R"
  4. AU="Koh, Lian Chye Winston"
  5. AU="Meredith M. White"
  6. AU="Aft, Rebecca"
  7. AU="Urban, Gerald A"
  8. AU="Jeong, Jae-Hyun"
  9. AU="Patsch, Wolfgang"
  10. AU="Garwood, Sarah K"
  11. AU="Pilon, Dominic"
  12. AU="Ignacio Cerro, C"
  13. AU=Jethani Bipin AU=Jethani Bipin

Suchergebnis

Treffer 1 - 2 von insgesamt 2

Suchoptionen

  1. Artikel ; Online: Correction to: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.

    Rose, Tracy L / Weir, William H / Mayhew, Gregory M / Shibata, Yoichiro / Eulitt, Patrick / Uronis, Joshua M / Zhou, Mi / Nielsen, Matthew / Smith, Angela B / Woods, Michael / Hayward, Michele C / Salazar, Ashley H / Milowsky, Matthew I / Wobker, Sara E / McGinty, Katrina / Millburn, Michael V / Eisner, Joel R / Kim, William Y

    British journal of cancer

    2022  Band 126, Heft 8, Seite(n) 1237

    Sprache Englisch
    Erscheinungsdatum 2022-03-11
    Erscheinungsland England
    Dokumenttyp Published Erratum
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/s41416-022-01781-y
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh III Zs.142: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.

    Rose, Tracy L / Weir, William H / Mayhew, Gregory M / Shibata, Yoichiro / Eulitt, Patrick / Uronis, Joshua M / Zhou, Mi / Nielsen, Matthew / Smith, Angela B / Woods, Michael / Hayward, Michele C / Salazar, Ashley H / Milowsky, Matthew I / Wobker, Sara E / McGinty, Katrina / Millburn, Michael V / Eisner, Joel R / Kim, William Y

    British journal of cancer

    2021  Band 125, Heft 9, Seite(n) 1251–1260

    Abstract: Background: FGFR3-altered urothelial cancer (UC) correlates with a non-T cell-inflamed phenotype and has therefore been postulated to be less responsive to immune checkpoint blockade (ICB). Preclinical work suggests FGFR3 signalling may suppress ... ...

    Abstract Background: FGFR3-altered urothelial cancer (UC) correlates with a non-T cell-inflamed phenotype and has therefore been postulated to be less responsive to immune checkpoint blockade (ICB). Preclinical work suggests FGFR3 signalling may suppress pathways such as interferon signalling that alter immune microenvironment composition. However, correlative studies examining clinical trials have been conflicting as to whether FGFR altered tumours have equivalent response and survival to ICB in patients with metastatic UC. These findings have yet to be validated in real world data, therefore we evaluated clinical outcomes of patients with FGFR3-altered metastatic UC treated with ICB and investigate the underlying immunogenomic mechanisms of response and resistance.
    Methods: 103 patients with metastatic UC treated with ICB at a single academic medical center from 2014 to 2018 were identified. Clinical annotation for demographics and cancer outcomes, as well as somatic DNA and RNA sequencing, were performed. Objective response rate to ICB, progression-free survival, and overall survival was compared between patients with FGFR3-alterations and those without. RNA expression, including molecular subtyping and T cell receptor clonality, was also compared between FGFR3-altered and non-altered patients.
    Results: Our findings from this dataset confirm that FGFR3-altered (n = 17) and wild type (n = 86) bladder cancers are equally responsive to ICB (12 vs 19%, p = 0.73). Moreover, we demonstrate that despite being less inflamed, FGFR3-altered tumours have equivalent T cell receptor (TCR) diversity and that the balance of a CD8 T cell gene expression signature to immune suppressive features is an important determinant of ICB response.
    Conclusions: Our work in a real world dataset validates prior observations from clinical trials but also extends this prior work to demonstrate that FGFR3-altered and wild type tumours have equivalent TCR diversity and that the balance of effector T cell to immune suppression signals are an important determinant of ICB response.
    Mesh-Begriff(e) Adult ; Aged ; Aged, 80 and over ; CD8-Positive T-Lymphocytes/metabolism ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/genetics ; Carcinoma, Transitional Cell/immunology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Immune Checkpoint Inhibitors/administration & dosage ; Immune Checkpoint Inhibitors/pharmacology ; Male ; Middle Aged ; Receptor, Fibroblast Growth Factor, Type 3/genetics ; Receptors, Antigen, T-Cell/metabolism ; Retrospective Studies ; Sequence Analysis, DNA ; Sequence Analysis, RNA ; Survival Analysis ; Treatment Outcome ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/genetics ; Urinary Bladder Neoplasms/immunology
    Chemische Substanzen Immune Checkpoint Inhibitors ; Receptors, Antigen, T-Cell ; FGFR3 protein, human (EC 2.7.10.1) ; Receptor, Fibroblast Growth Factor, Type 3 (EC 2.7.10.1)
    Sprache Englisch
    Erscheinungsdatum 2021-07-22
    Erscheinungsland England
    Dokumenttyp Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 80075-2
    ISSN 1532-1827 ; 0007-0920
    ISSN (online) 1532-1827
    ISSN 0007-0920
    DOI 10.1038/s41416-021-01488-6
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Uh III Zs.142: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang